Q/C Technologies, Inc.

QCLS

Nasdaq; healthcare; SIC 2835, In Vitro & In Vivo Diagnostic Substances; CIK 0001321834

None

No letter

4 of 13 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $41.2M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	short runway, late filer, thin data not computable: dilution, fortress balance sheet
Inputs computable	4 of 13
Graded from	filings received through Apr 29, 2026 206 days before the rescan; latest periodic filing 10-Q received Nov 16, 2026
Last close	$0.28 2026-11-20; market equity $2.4M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Apr 15, 2026

Technologies, Inc. (the "Company") has historically been engaged in the development and commercialization of therapeutic platforms based on well-defined biological targets, including Isomyosamine and Supera-CBD. More recently, the Company has shifted its business strategy to focus on energy-efficient blockchain and cryptocurrency infrastructure through quantum-class laser-based Company's core strategy is centered on leveraging an exclusive global licensing agreement with LightSolver Ltd. ("LightSolver") to deploy innovative laser processing units ("LPUs"), including the Company-branded qc-LPU100? (the "qc-LPU100").

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 46.9						
Gross profitability	not computable	32.8%				

latest aligned inputs end 2019-12-31; latest annual assets end 2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Return on invested capital	not computable	9.6%				
one or more required annual facts are missing						
Accruals ratio	(8.2%)	(6.7%)		46.9	756	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
latest aligned inputs end 2019-12-31; latest annual assets end 2025-12-31						
Solvency, sleeve percentile 59.8						
Altman Z double-prime	(9.87)	0.31		62.5	705	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(3.61x)				
one or more required annual facts are missing						
Current ratio	3.00x	2.68x		57.2	781	2025-12-31
Growth and financing, sleeve percentile 14.0						
Revenue growth, three-year compound	not computable	9.6%				
latest aligned inputs end 2019-12-31; latest annual assets end 2025-12-31						
Free cash flow growth, three-year compound	not computable	11.1%				
four consecutive annual FCF observations are required; found 6						
Reinvestment rate	not computable	33.9%				
NOPAT must exceed $100,000						
Asset growth, three years	32.9%	3.2%		14.0	663	2025-12-31
Net share issuance, one year	not computable	1.6%				
prior share count is 15 days earlier						

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 3.2 months
Late filer	found 4 NT 10-K/Q filings in the last eight quarters
Thin data	4 of 13 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-20 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(78.5%)	(1.7%)	5
Distance from 52-week high	(96.0%)	(33.0%)	2
EBIT to enterprise value	not computable	0.5%	
Free cash flow yield	(450.7%)	0.6%	1
Book value to price	6.72	0.29	98
Sales to price	0.66	0.38	66
Composite equity issuance, five years	804.1%	13.5%	99
Relative strength against the sector, log excess return	(1.71)	(0.19)	5
Twelve-month failure probability, CHS model	1.40%	0.06%	86

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail

Cash, filings, liquidity

Cash and equivalents	$2.6M
Operating cash flow, four quarters	-$9.8M
Months of runway	3.2
Days since last periodic filing	5 (10-Q received Nov 16, 2026)
Median daily dollar volume, 63 sessions	$172,346

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$478,747	2019-12-31	2020-03-25	10-K	20-004650
2	assets	us-gaap:Assets	$10.9M	2019-12-31	2021-03-01	10-K	21-005129
3	net income	us-gaap:NetIncomeLoss	-$11.6M	2025-12-31	2026-04-15	10-K	26-016872
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$9.1M	2025-12-31	2026-04-15	10-K	26-016872
5	assets	us-gaap:Assets	$41.2M	2025-12-31	2026-04-15	10-K	26-016872
6	assets	us-gaap:Assets	$21.4M	2024-12-31	2026-04-15	10-K	26-016872
7	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.6M	2019-12-31	2020-03-25	10-K	20-004650
8	gross profit	us-gaap:GrossProfit	$127,285	2018-12-31	2020-03-25	10-K	20-004650
9	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.7M	2018-12-31	2020-03-25	10-K	20-004650
10	gross profit	us-gaap:GrossProfit	$948,580	2017-12-31	2019-04-01	10-K	19-004590
11	revenue	us-gaap:Revenues	$3.4M	2017-12-31	2018-07-13	10-K/A	18-009979
12	gross profit	us-gaap:GrossProfit	$1.9M	2016-12-31	2018-07-13	10-K/A	18-009979
13	revenue	us-gaap:Revenues	$3.0M	2016-12-31	2018-07-13	10-K/A	18-009979
14	gross profit	us-gaap:GrossProfit	$1.2M	2015-12-31	2017-04-11	10-K	17-003722
15	revenue	us-gaap:Revenues	$2.1M	2015-12-31	2017-04-11	10-K	17-003722
16	current assets	us-gaap:AssetsCurrent	$16.6M	2025-12-31	2026-04-15	10-K	26-016872
17	current liabilities	us-gaap:LiabilitiesCurrent	$5.5M	2025-12-31	2026-04-15	10-K	26-016872
18	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$144.1M	2025-12-31	2026-04-15	10-K	26-016872
19	operating income	us-gaap:OperatingIncomeLoss	-$9.8M	2025-12-31	2026-04-15	10-K	26-016872
20	book equity	us-gaap:StockholdersEquity	$21.8M	2025-12-31	2026-04-15	10-K	26-016872
21	liabilities	us-gaap:Liabilities	$16.4M	2025-12-31	2026-04-15	10-K	26-016872
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$112,951	2015-12-31	2017-04-11	10-K	17-003722
23	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$299,995	2015-12-31	2017-04-11	10-K	17-003722
24	operating income	us-gaap:OperatingIncomeLoss	-$9.7M	2015-12-31	2017-04-11	10-K	17-003722
25	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$9.6M	2015-12-31	2017-04-11	10-K	17-003722
26	income tax	us-gaap:IncomeTaxExpenseBenefit	-$269,344	2015-12-31	2017-04-11	10-K	17-003722
27	current assets	us-gaap:AssetsCurrent	$6.5M	2015-12-31	2017-04-11	10-K	17-003722
28	current liabilities	us-gaap:LiabilitiesCurrent	$1.7M	2015-12-31	2017-04-11	10-K	17-003722
29	current assets	us-gaap:AssetsCurrent	$13.1M	2014-12-31	2016-03-30	10-K	16-008364
30	current liabilities	us-gaap:LiabilitiesCurrent	$1.8M	2014-12-31	2016-03-30	10-K	16-008364
31	assets	us-gaap:Assets	$17.9M	2023-12-31	2025-04-11	10-K	25-003814
32	assets	us-gaap:Assets	$17.5M	2022-12-31	2024-04-01	10-K	24-012533
33	shares outstanding	dei:EntityCommonStockSharesOutstanding	7,853,429	2026-04-27	2026-04-29	10-K/A	26-019663
34	shares outstanding	dei:EntityCommonStockSharesOutstanding	7,853,429	2026-04-12	2026-04-15	10-K	26-016872

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.